Eric E. Fortess

TL;DR: 20 years of research on cost sharing, drug reimbursement limits, and administrative limitations on access to particular drugs via formularies, category exclusions, or prior authorization requirements are reviewed; their methodological rigor is evaluated; the state of current knowledge is summarized; and future research directions are proposed.

TL;DR: The sudden withdrawal of zomepirac from the market resulted in substitutions not only of other NSAIDs, but also of alternative analgesics that carry risks of habituation and adverse effects.

TL;DR: To identify specific characteristics of patients, physicians, and treatment settings associated with decreased receipt of essential medications in a chronically ill, older population following a Medicaid three‐prescription monthly reimbursement limit (cap).

TL;DR: In this article, the authors conducted telephone interviews with key informants in Medicaid programs that had recently made changes in cost-sharing policies and found that the barriers to evidence-based policy making were lack of political power, skills, and infrastructure; crisis-oriented decisions; compartmentalized budgeting; lack of advocates for disadvantaged patients; and the absence of timely research.

TL;DR: The growing demand for prospective evaluation enhances the popularity of cost-effective ness analysis, a technique for identifying best uses of scarce resources, as the evaluative comparison of monetary and nonmonetary dimensions of impact.